Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Seliciclib, also known as roscovitine, is a selective and potent inhibitor of cyclin-dependent kinases (CDKs) that has demonstrated potential in the treatment of cancer and other diseases. It inhibits CDK2, CDK7, and CDK9, which play crucial roles in cell cycle regulation and transcription. By inhibiting these kinases, Seliciclib leads to cell cycle arrest and suppression of transcription of key proteins necessary for tumor growth and progression. Its anti-cancer activity has been observed in preclinical studies, and it has been investigated in clinical trials for various cancers, as well as for neurological and inflammatory diseases. Further research is required to fully understand its therapeutic potential and safety profile in humans.

186692-44-4

Post Buying Request

186692-44-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol

    Cas No: 186692-44-4

  • USD $ 1.9-2.9 / Gram

  • 100 Gram

  • 1000 Metric Ton/Month

  • Chemlyte Solutions
  • Contact Supplier

186692-44-4 Usage

Uses

Used in Cancer Treatment:
Seliciclib is used as an anti-cancer agent for its ability to inhibit CDKs involved in cell cycle regulation and transcription. This leads to cell cycle arrest and suppression of transcription of proteins required for tumor growth and progression, making it a promising candidate for the treatment of various cancers, including breast, lung, and colorectal cancer.
Used in Neurological and Inflammatory Disease Treatment:
Seliciclib has also shown potential in the treatment of neurological and inflammatory diseases due to its inhibitory effects on CDKs. The modulation of these kinases may help in managing the progression of these diseases and improving patient outcomes.

Check Digit Verification of cas no

The CAS Registry Mumber 186692-44-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,6,6,9 and 2 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 186692-44:
(8*1)+(7*8)+(6*6)+(5*6)+(4*9)+(3*2)+(2*4)+(1*4)=184
184 % 10 = 4
So 186692-44-4 is a valid CAS Registry Number.
InChI:InChI=1/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)

186692-44-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name (2S)-2-{[6-(Benzylamino)-9-isopropyl-9H-purin-2-yl]amino}-1-butan ol

1.2 Other means of identification

Product number -
Other names 5-formylpentyl benzoate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:186692-44-4 SDS

186692-44-4Relevant articles and documents

The first iron(III) complexes with cyclin-dependent kinase inhibitors: Magnetic, spectroscopic (IR, ES+ MS, NMR, 57Fe M?ssbauer), theoretical, and biological activity studies

Trávní?ek, Zdeněk,Popa, Igor,?ajan, Michal,Zbo?il, Radek,Kry?tof, Vladimír,Mikulík, Ji?í

, p. 405 - 417 (2011/12/22)

The first FeIII complexes 1-6 with cyclin-dependent kinase (CDK) inhibitors of the type [Fe(Ln)Cl3]·nH2O (n=0 for 1, 1 for 2, 2 for 3-6; L1-L6=C2- and phenyl-substituted CDK inhibitors derived from 6-benzylamino-9-isopropylpurine), have been synthesized and characterized by elemental analysis, IR, 57Fe Mo?ssbauer, 1H and 13C NMR, and ES+ mass spectroscopies, conductivity and magnetic susceptibility measurements, and thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). The study revealed that the compounds are mononuclear, tetrahedral high-spin (S=5/2) FeIII complexes with an admixture of an S=3/2 spin state originating probably from five-coordinated FeIII ions either connecting with a bidentate coordination mode of the CDK inhibitor ligand or relating to the possibility that one crystal water molecule enters the coordination sphere of the central atom in a portion of molecules of the appropriate complex. Nearly spin-only value of the effective magnetic moment (5.82μeff/μB) was determined for compound 1 due to absence of crystal water molecule(s) in the structure of the complex. Based on NMR data and DFT calculations, we assume that the appropriate organic ligand is coordinated to the FeIII ion through the N7 atom of a purine moiety. The cytotoxicity of the complexes was tested in vitro against selected human cancer cell lines (G-361, HOS, K-562 and MCF-7) along with the ability to inhibit the CDK2/cyclinE kinase. The best cytotoxicity (IC50: 4-23μM) and inhibition activity (IC50: 0.02-0.09μM) results have been achieved in the case of complexes 2-4, and complexes 3, 4 and 6, respectively. In addition, the X-ray structure of 2-chloro-6-benzylamino-9-isopropylpurine, i.e. a precursor for the preparation of L1, L4 and L5, is also described.

Cytokinin-derived cyclin-dependent kinase inhibitors: Synthesis and cdc2 inhibitory activity of olomoucine and related compounds

Havlí?ek, Libor,Hanu?, Jan,Vesely, Jaroslav,Leclerc, Sophie,Meijer, Laurent,Shaw, Gordon,Strnad, Miroslav

, p. 408 - 412 (2007/10/03)

Cyclin-dependent kinases (cdk) have recently raised considerable interest in view of their essential role in the regulation of the cell division cycle. The structure-activity relationships of edk inhibition showed that the 1, 3, and 7 positions of the purine ring must remain free, probably for a direct interaction, in which it behaves as a hydrogen bond acceptor. Olomoucine (6-(benzylamino)-2-[(2-hydroxyethyl)amino]-9-methylpurine, OC), roscovitine (6-(benzylamino)2(R)-[[1-(hydroxymethyl)propyl]amino]-9- isopropylpurine), and other N6,2,9-trisubstituted adenines were found to exert a strong inhibitory effect on the p34(cdc2)/cyclin B kinase. Removal or change of the side chain at position 2 or the hydrophobic group at position 9 dramatically decreased the inhibitory activity of olomoucine or roscovitine. Inhibition of cdk with OC and related compounds clearly arrests cell proliferation of many tumor cell lines at G1/S and G2/M transitions and also triggers apoptosis in the target tumor cells in vitro and in vivo. Thus, from a pharmacological point of view, OC may represent a model compound for a new class of antimitotic and antitumor drugs.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 186692-44-4